A variety of studies including ours have indicated that HER2 expression on both DTCs and CTCs differed from HER2 expression in the primary tumor and that the expression of HER2 on DTCs and CTCs was correlated with poor prognosis16, 44. This evidence concerns the gene ERBB2 and neoplasm.